The influence of levosimendan and iloprost on renal ischemia-reperfusion: An experimental study

Interactive Cardiovascular and Thoracic Surgery

Volumn 7, Issue 2, 2008, Pages 235-239

  Yakut, Necmettin ^a   Yasa, Haydar ^a,b   Lafci, Banu Bahriye ^a   Ortac, Ragip ^a   Tulukoglu, Engin ^a   Aksun, Murat ^a   Ozbek, Cengiz ^a   Gurbuz, Ali ^a  

^a ATATURK TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b NONE   (Turkey)

Author keywords

Iloprost; Ischemia reperfusion injury; Levosimendan; Rabbit kidney

Indexed keywords

BICARBONATE; ILOPROST; LEVOSIMENDAN; MALONALDEHYDE; PENTOXIFYLLINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATROPHY; BIOCHEMISTRY; CARBON DIOXIDE TENSION; CONTINUOUS INFUSION; CONTROL GROUP; CONTROLLED STUDY; DIASTOLE; DRUG EFFICACY; DRUG TOLERABILITY; EXPERIMENTAL RABBIT; EXPERIMENTAL STUDY; FEMALE; HEART HEMODYNAMICS; HEART RATE; HISTOPATHOLOGY; KIDNEY INJURY; KIDNEY ISCHEMIA; KIDNEY TUBULE NECROSIS; LOADING DRUG DOSE; MALE; NONHUMAN; OXYGEN TENSION; PH; PRIORITY JOURNAL; REPERFUSION INJURY; STATISTICAL SIGNIFICANCE; SYSTOLE; TISSUE LEVEL; TISSUE REGENERATION; TREATMENT DURATION;

ANIMALS; ATROPHY; DISEASE MODELS, ANIMAL; FEMALE; HYDRAZONES; ILOPROST; KIDNEY; KIDNEY DISEASES; LIPID PEROXIDATION; MALE; MALONDIALDEHYDE; NECROSIS; PROTECTIVE AGENTS; PYRIDAZINES; RABBITS; REPERFUSION INJURY;

EID: 41849106827     PISSN: 15699293     EISSN: None     Source Type: Journal    
DOI: 10.1510/icvts.2007.161356     Document Type: Article

References (24)

1. Adams JG Jr, Dhar A, Shukla SD, Silver D. Effect of pentoxifillin on tissue injury and platelet - activating factor production during ischemia-reperfusion injury. J Vasc Surg 1995;21:742-748.
2. Troyer-Caudle J. Reperfusion injury. J Vasc Nurs 1993;11:76-79.
3. Sucu N, Unlu A, Tamer L, Aytacoglu B, Coskun B, Bilgin R, et al. Effects of trimetazidine on tissue damage in kidney after hindlimb ischemia-reperfusion. Pharmacol Res 2002;46:345-349.
4. Neary P, Redmond HP. Ischemia-reperfusion injury and the systemic inflammatory response syndrome. Grace PA, Mathie RT, editors. Ischemia-reperfusion injury. London: Blackwell Science; 1999, p.123-136.
5. Fantone JC, Marasco WA, Elgas LJ, Ward PA. Stimulus specifity of prostaglandin inhibition of rabbit polymorphonuclear leukocyte lysosomal enzyme release and superoxide anion production. Am J Pathol 1984;115:9-16.
6. Simpson PJ, Mitsos SE, Ventura A, Gallagher KP, Fantone JC, Abrams GD, Schork MA, Lucchesi BR. Prostacyclin protects ischemic reperfused myocardium in the dog by inhibition of neutrophil activation. Am Heart J 1987;113:129-137.
7. Follath F, Cleland JG, Just H. Steering Committee, Investigators of the Levosimendan Infusion versus Dobutamine (LIDO) study. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomized double blind trial. Lancet 2002;360:196-202.
8. Parissis J, Adamopoulos S, Antoniades C, Kostakis G, Rigas A, Kryzopoulos S, Iliodromitis E, Kremastinos D. Effects of levosimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure. Am J Cardiol 2004;93:1309-1312.
9. Emrecan B, Tulukoglu E, Bozok S, Kestelli M, Onem G, Kupelioglu A, Yagdi S, Gurbuz A. Effects of iloprost and pentoxyfillin on renal ischemia-reperfusion in rabbit model. Eur J Med Res 2006;11:1-5.
10. Crinnion JN, Homer-Vanniasinkam S, Gough MJ. Skeletal muscle reperfusion injury: pathophysiology and clinical considerations. Cardiovasc Surg 1993;1:317-324.
11. Mazzone A, Mazzucchelli I, Fossati G, Gritti D, Girola S, Canale C, et al. Iloprost effects on phagocytes in patients suffering from ischaemic diseases: in vivo evidence for down regulation of αMβ2 integrin. Eur J Clin Invest 1996;26:860-866.
12. Carden DL, Granger DL. Pathophysiology of ischemia-reperfusion injury. J Pathol 2000;190:255-266.
13. Mizutani A, Okajima K, Uchiba M, Noguchi T. Activated protein C reduces ischemiayreperfusion-induced renal injury in rats by inhibiting leukocyte activation. Blood 2000;95:3781-3787.
14. Belkin M, Wright JG, Hobson RW. Iloprost infusion decreases skeletal muscle ischemia-reperfusion injury. J Vasc 1990;11:77-83.
15. Haikala H, Kaivola J, Nissinen E, Wall P, Levijoki J, Linden I-B. Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan. J Mol Cell Cardiol 1995;27:1859-1866.
16. Bowman P, Haikala H, Paul RJ. Levosimendan, a calcium smooth sensitizer in cardiac muscle, induces relaxation in coronary smooth muscle through calcium desensitization. J Pharmacol Exp Ther 1999;288:316-325.
17. Yokoshiki H, Katsube Y, Sunagawa M, Speralakis N. Levosimendan, a novel Ca sensitizer, activates the glibenclamide-sensitize K channel in rat arterial myocytes. Eur J Pharmacol 1996;333:249-259.
18. Kertsen JR, Montgomery MW, Pagel PS, Warltier DC. Levosimendan, a new positive inotropic drug, decreases myocardial infarct size via activation of K(ATP) channels. Anesth Analg 2000;90:5-11.
19. Cetinkale O, Bilgiç L, Bolayirli M, Sengül R, Ayan F, Burcak G. Involvement of neutrophils in ischemia-reperfüsion injury of inguinal island skin flaps in rats. Plast Reconstr Surg 1998;102:153-160.
20. Lindsay T, Romaschin A, Walker PM. Free radical mediated damage in skeletal muscle. Microcirc Endothelium Lymphatics 1989;5:157-170.
21. McCord JM. The evaluation of free radicals and oxidative stress. Am J Med 2000;108:652-659.
22. Draper HH, Hadley M. Malonaldehyde determination as index of lipid peroxidation. In: Parker L, Glazer A, editors. Methods in enzymology. New York: Academic Press, 1991;186: p. 421-431.
23. Onal A, Astarcioǧlu H, Ormen M, Atila K, Sarioǧlu S. The beneficial effect of L-carnitine in rat renal ischemia-reperfusion injury. Ulus Travma Dergisi 2004;10:160-167.
24. Uchiyama M, Mihara M. Determination of malonaldehyde precursor in tissues by thiobarbituric acid test. Anal Biochem 1978;86:271-278.